What is claimed is:

~~1. The compound esomeprazole or 5-O-desmethyl-omeprazole or a therapeutically acceptable salt, solvate, prodrug or stereoisomer thereof, or a pharmaceutical composition esomeprazole or 5-O- desmethyl-omeprazole or a therapeutically acceptable salt, solvate, prodrug or stereoisomer thereof for use in the treatment of a disease in a subject in need thereof, wherein the disease is selected from the group consisting of schizophrenia, schizoaffective disorder, mild cognitive impairment (MCI), depression, Tourette Syndrome, ataxia, Post traumatic stress disorder (PTSD) Obsessive-compulsive disorder (OCD), Alzheimer's disease, Parkinson's disease, dementia, loss of memory and/or cognition associated with neurodegenerative diseases, loss of neuronal function characteristic of neurodegenerative diseases, pain and convulsion.~~

~~2. The compound of Claim 1, wherein the effective amount of the compound is 2 mg/kg body weight to 5 g/kg body weight.~~

~~3. The compound of Claim 1, wherein the disease is treated via DAAO inhibition.~~

~~4. The compound of Claim 1, wherein the schizophrenia and schizoaffective disorder include negative, cognitive, positive and general psychopathology symptom domains.~~

~~5. The compound of Claim 1, wherein the disease is MCI, Alzheimer's disease, Parkinson's disease or schizophrenia.~~

~~6. The compound of Claim 1, wherein the disease is pain, ataxia and convulsion.~~

~~7. The compound of Claim 1, wherein the disease is schizoaffective disorder.~~

~~8. The compound of Claim 1, wherein the disease is depression or Tourette Syndrome.~~

~~9. The compound of Claim 1, wherein the disease is PTSD or OCD.~~

~~10. The compound of Claim 1, wherein the disease is dementia, loss of memory and/or cognition associated with neurodegenerative diseases or loss of neuronal function characteristic of neurodegenerative diseases.~~

~~11. The compound of Claim 1, wherein the subject is a human.~~

~~12. The compound of Claim 1, wherein the pharmaceutical composition comprises a pharmaceutical acceptable carrier and/or an excipient.~~

~~13. The compound of Claim 1, wherein the compound esomeprazole or 5-O-desmethyl-omeprazole or a therapeutically acceptable salt, solvate, or stereoisomer thereof or the pharmaceutical composition is administered to the subject orally, parenterally, intravenously, intramuscularly, intraperitoneally, intrasternally, subcutaneously, intramedullary, intraarticularly, intraduodenally, transdermally, by nasal aerosol, by inhalation, by rectal administration, or by vaginal administration.~~

~~14~~1. Use of ~~the compound~~ esomeprazole or 5-O-desmethyl-omeprazole (RS-D7) or a therapeutically acceptable salt, solvate~~, prodrug~~ or stereoisomer thereof~~, or a pharmaceutical composition esomeprazole or 5-O-desmethyl-omeprazole or a therapeutically acceptable salt, solvate, prodrug or stereoisomer thereof~~ in the manufacture of a medicament for ~~the treatment of~~treating and/or preventing a disease ~~in a subject in need thereof, wherein the disease is selected from the group consisting of schizophrenia, schizoaffective disorder, mild cognitive impairment (MCI), depression, Tourette Syndrome, ataxia, Post-traumatic stress disorder (PTSD) Obsessive-compulsive disorder (OCD), Alzheimer's disease, Parkinson's disease, dementia, loss of memory and/or cognition~~ associated with ~~neurodegenerative diseases, loss of neuronal function characteristic of neurodegenerative diseases, pain and convulsion~~D-amino acid oxidase (DAAO) inhibition in a human.

~~15~~2. The use of Claim ~~14~~1, wherein the effective amount of the compound or a therapeutically acceptable salt, solvate or stereoisomer thereof is 2 mg/kg body weight to 5 g/kg body weight.

~~16~~3. The use of Claim ~~14~~1 or 2, wherein the disease associated with DAAO inhibition is selected from the group consisting of schizophrenia, schizoaffective disorder, mild cognitive impairment (MCI), depression, Tourette Syndrome, ataxia, Post-traumatic stress disorder (PTSD), Obsessive-compulsive disorder (OCD), pain, convulsion, dementia, loss of

memory and/or cognition associated with neurodegenerative diseases and loss of neuronal function characteristic of neurodegenerative diseases~~is treated via DAAO inhibition~~.

~~17~~4. The use of Claim ~~14~~3, wherein the schizophrenia and schizoaffective disorder include negative, cognitive, depressive, positive and general psychopathology symptom domains.

~~18~~5. The use of Claim ~~14~~3, wherein the disease associated with DAAO inhibition is mild cognitive impairment (MCI), Alzheimer's disease, Parkinson's disease or schizophrenia.

~~19~~6. The use of Claim ~~14~~3, wherein the disease associated with DAAO inhibition is pain, ataxia or convulsion.

~~20. The use of Claim 14, wherein the disease is schizoaffective disorder.~~

~~21. The use of Claim 14, wherein the disease is depression or Tourette Syndrome.~~

~~22. The use of Claim 14, wherein the disease is PTSD or OCD.~~

~~23. The use of Claim 14, wherein the disease is dementia, loss of memory and/or cognition associated with neurodegenerative diseases or loss of neuronal function characteristic of neurodegenerative diseases.~~

~~24. The use of Claim 14, wherein the subject is a human.~~

~~25~~7. The use of any one of Claims ~~14~~1-6, wherein the medicament is a pharmaceutical composition ~~comprises a~~comprising pharmaceutical acceptable carriers and/or ~~an~~ excipients.

~~26~~8. The use of any one of Claims ~~14~~1-7, wherein the ~~compound esomeprazole or 5-O-desmethyl-omeprazole or a therapeutically acceptable salt, solvate, prodrug or stereoisomer thereof or the pharmaceutical composition is administered to the subject~~medicament for oral~~ly~~, parenteral~~ly~~, intravenous~~ly~~, intramuscular~~ly~~, intraperitoneal~~ly~~, intrasternal~~ly~~, subcutaneous~~ly~~, intramedullary, intraarticular~~ly~~, infusion, intrathecal, epidural, intraduodenal~~ly~~, transdermal~~ly~~, ~~by~~ nasal aerosol, ~~by~~ inhalation, ~~by~~ rectal ~~administration,~~ or ~~by~~ vaginal administration.